Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Enterprise Value (2020 - 2023)

Candel Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$43.0 million for Q3 2023.

  • For Q3 2023, Enterprise Value rose 44.31% year-over-year to -$43.0 million; the TTM value through Sep 2023 reached -$43.0 million, up 44.31%, while the annual FY2022 figure was -$70.1 million, 15.23% up from the prior year.
  • Enterprise Value for Q3 2023 was -$43.0 million at Candel Therapeutics, up from -$51.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$24.3 million in Q2 2021 and bottomed at -$94.3 million in Q1 2022.
  • The 4-year median for Enterprise Value is -$70.1 million (2022), against an average of -$64.8 million.
  • The largest annual shift saw Enterprise Value plummeted 256.89% in 2022 before it skyrocketed 44.31% in 2023.
  • A 4-year view of Enterprise Value shows it stood at -$35.1 million in 2020, then tumbled by 135.76% to -$82.6 million in 2021, then rose by 15.23% to -$70.1 million in 2022, then soared by 38.65% to -$43.0 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Enterprise Value are -$43.0 million (Q3 2023), -$51.9 million (Q2 2023), and -$59.3 million (Q1 2023).